ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$1.06 USD
-0.03 (-2.75%)
Updated Jun 4, 2024 03:58 PM ET
After-Market: $1.06 0.00 (0.00%) 7:12 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IPA 1.06 -0.03(-2.75%)
Will IPA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IPA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPA
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
New Strong Buy Stocks for February 7th
IPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for February 5th
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
New Strong Buy Stocks for October 23rd
Other News for IPA
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
BioStrand Leads Innovation in Precision Medicine
ImmunoPrecise Antibodies announces expansion of LENS platform
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
ImmunoPrecise Antibodies, InterSystems partner to leverage AI in life sciences